

**CORRIGENDUM**

**Corrigendum to ‘Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers’**



[ESMO Open volume 7 (2022) 10.1016/j.esmoop.2022.100401]

**A. Samani<sup>1,2</sup>, R. Bennett<sup>2</sup>, K. Ereishvili<sup>3</sup>, F. Kalofonou<sup>2</sup>, S. Whear<sup>1</sup>, A. Montes<sup>3</sup>, R. Kristeleit<sup>3</sup>, J. Krell<sup>1,2</sup>, I. McNeish<sup>1,2</sup>, S. Ghosh<sup>3</sup> & L. Tookman<sup>1,2\*</sup>**

<sup>1</sup> Department of Surgery and Cancer, Imperial College London, London; <sup>2</sup> Department of Medical Oncology, Imperial College Healthcare NHS Trust, London; <sup>3</sup> Guy's Cancer Centre, Guy's and St. Thomas' NHS Foundation Trust, London, UK

The authors regret that in the original publications of these articles the author disclosures were incomplete. The correct disclosures should read as follows:

Amit Samani - no conflicts; Laura Tookman has served on advisory boards for AstraZeneca and Clovis Oncology, received consulting fees from Tesaro and honoraria for lectures and presentations from Clovis Oncology, GSK, AstraZeneca and MSD; Jonathan Krell has served on advisory boards for Clovis Oncology, AstraZeneca, and Tesaro; Iain McNeish has served on advisory boards for Clovis Oncology, AstraZeneca, Takeda, and Tesaro and receives institutional funding from AstraZeneca. Sharmistha Ghosh declares Honoraria and consulting or advisory role: AstraZeneca, Chugai, Merck Sharp & Dohme, Pfizer, Roche, Takeda. The remaining authors have declared no conflicts of interest.

**and to ‘Response to the letter entitled “Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers”’**

[ESMO Open volume 7 (2022) 10.1016/j.esmoop.2022.100534]

**A. Samani<sup>1,2</sup>, J. Krell<sup>1,2</sup>, I. McNeish<sup>1,2</sup> & L. Tookman<sup>1,2</sup>**

<sup>1</sup> Department of Surgery and Cancer, Imperial College London; <sup>2</sup> Department of Medical Oncology, Hammersmith Hospital, London, UK

The authors regret that in the original publications of these articles the author disclosures were incomplete. The correct disclosures should read as follows:

All declarations of interest are outside the scope of the work published and unrelated to the work. Amit Samani - no conflicts; Laura Tookman has served on advisory boards for AstraZeneca and Clovis Oncology, received consulting fees from Tesaro and honoraria for lectures and presentations from Clovis Oncology, GSK, AstraZeneca and MSD; Jonathan Krell has served on advisory boards for Clovis Oncology, AstraZeneca, and Tesaro; Iain McNeish has served on advisory boards for Clovis Oncology, AstraZeneca, Takeda, and Tesaro and receives institutional funding from AstraZeneca.

The authors would like to apologise for any inconvenience caused.

DOI of original articles: <https://doi.org/10.1016/j.esmoop.2022.100401>, <https://doi.org/10.1016/j.esmoop.2022.100534>

\*Correspondence to: Dr Laura Tookman, Department of Medical Oncology, Hammersmith Hospital, 72 Du Cane Road, London, W12 0HS, UK  
E-mail: [l.tookman@imperial.ac.uk](mailto:l.tookman@imperial.ac.uk) (L. Tookman).

2059-7029/Crown Copyright © 2022 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. All rights reserved.